

## AMENDMENTS TO THE CLAIMS

1. (Currently Amended). A therapeutic solution comprised of filtered seawater and ~~firstly administered~~ in the form of an aerosolized solution in the respiratory tract of mammals, said therapeutic solution having a direct effect in respiratory tissues and secretions as expectorant, mucolytic, decongestant and virucidal, wherein said filtered seawater comprises approximately from 277.00 to 555.00 millimoles per liter of sodium, 417.00 to 894.00 millimoles per liter of chloride, 9.80 to 11.70 millimoles per liter of potassium, 20.90 to 26.13 millimoles per liter of sulfate, 45.60 to 60.49 millimoles per liter of magnesium, and 8.11 to 10.87 millimoles per liter of calcium, wherein osmolality is from 920 to 1,130 mOsm/Kg and pH is between 5.7 and 6.8.
2. (Canceled).
3. (Canceled).
4. (Original). The therapeutic solution set forth in claim 3, further characterized in that said filtered seawater comprises trace elements and a therapeutic solvent, said therapeutic solvent is said seawater.
5. (Currently Amended). The therapeutic solution set forth in claim 4, further characterized in that said therapeutic solution is ~~said firstly administered~~ by aerosol to said respiratory tract of

1 said mammals such that said therapeutic solution contacts  
2 areas where said mucosa secretions accumulate including nose,  
3 pharynx, larynx, trachea, bronchi, bronchioles and alveoli.  
4

5 6. (Currently Amended). The therapeutic solution set forth in  
6 claim 5, further characterized in that said therapeutic solution is  
7 ~~secondly~~—administered by nebulization with a dose of  
8 approximately between one to ten ml via nasal or oral cavity to  
9 reach intratracheobronchial tissues and secretions with a  
10 varying frequency of administration according said mammals  
11 age group and clinical diagnosis, said nebulization every two to  
12 twelve hours and extending three to fifteen minutes, said  
13 therapeutic solution may be ~~thirdly~~—administered in a dry form  
14 through inhalations of one to three per time.  
15

16 7. (Currently Amended). The therapeutic solution set forth in  
17 claim 5, further characterized in that said therapeutic solution is  
18 ~~fourthly~~—administered with tents ~~and/or~~ or a vaporization  
19 system in a continuous form for up to twenty-four hours ~~or~~  
20 ~~more~~.  
21

22 8. (Currently Amended). A method ~~of affecting~~ for treating  
23 respiratory tissues and secretions as expectorant, mucolytic,  
24 decongestant and virucidal in a mammal in need thereof,  
25 comprising administering to said mammal an effective amount  
26 of a therapeutic solution, said therapeutic solution comprised of  
27 filtered seawater and ~~firstly~~ administered in the form of an  
28 aerosolized solution via nasal or cavity by nebulization with a

1 dose of approximately between one to ten ml. with varying  
2 frequency of administration according to said mammal's age  
3 group and clinical diagnosis, said nebulization administered  
4 every two to twelve hours, extending three to fifteen minutes to  
5 reach intratracheobronchial tissues and secretions and said  
6 solution increases the solubility and volume of the phlegm in a  
7 respiratory tract reducing the adhesiveness and making them  
8 easier to expel by means of coughing or suctioning, providing a  
9 symptomatic relief of cough and congestion associated with  
10 bronchial asthma, acute and chronic bronchitis and common  
11 colds, and wherein said solution increases output of said  
12 secretions from said respiratory tract by stimulating ciliary  
13 movement which facilitates the removal of mucus and said  
14 solution stimulates water transport into an airway lumen to  
15 decrease the inflammatory changes in a respiratory tree  
16 associated with bronchial asthma, chronic bronchitis and  
17 common colds.

18  
19 9. (Canceled).

20  
21 10. (Canceled).

22  
23 11. (Canceled).

24  
25 12. (Canceled).

26  
27 13. (Canceled).

28

1        14. (Original). A method of preparing a therapeutic solution,  
2            comprising:  
3

4        A) extracting seawater from a depth beyond where microscopic  
5 organism known as plankton lives, in an ocean;  
6

7        B) filtering said seawater to obtain desired concentration of  
8 elements, said elements primarily comprising sodium, magnesium,  
9 calcium, potassium, chloride, and sulfate;  
10

11       C) testing said seawater for microbiological and chemical analysis;  
12 and  
13

14       D) preparing a solution for packaging, having a predetermined  
15 approximated seawater element content as expectorant, mucolytic,  
16 decongestant, and virucidal.  
17

18       15. (New). The solution set forth in claim 12 wherein said solution  
19 is used as a vehicle for delivering drugs into the respiratory tract of a  
20 mammal.  
21  
22